Tumori最新文献

{"title":"Hospice admission of cancer patients receiving disease-modifying therapies near the end of life: implications for eligibility criteria.","authors":"Carla Bettini, Andrea Carlini, Laura Fabbri, Francesca Ghetti, Francesca Martini, Elisabetta Sansoni, Maria V Tenti, Paola Cravero, Lucia Angelini, Costanza M Donati, Alessio G Morganti, Romina Rossi, Marco C Maltoni","doi":"10.1177/03008916261446183","DOIUrl":"10.1177/03008916261446183","url":null,"abstract":"<p><strong>Purpose: </strong>This retrospective single-center observational study aimed to describe our experience of admitting patients based on palliative care needs rather than discontinuation of anticancer treatment.</p><p><strong>Methods: </strong>The study included all cancer patients admitted to Valerio Grassi Hospice while receiving disease modifying therapies (DMTs) in 2022. Functional status was assessed using the Eastern Cooperative Oncology Group Performance Status (ECOG PS) and the Palliative Prognostic Score (PaP score).</p><p><strong>Results: </strong>Thirty-one of the 150 included patients received DMTs in the last 30 days of life. Among these, five (16.1%) had an ECOG PS 2, 10 (32.3%) ECOG PS 3, and 16 (51.6%) ECOG PS 4. PaP scores were 0-5.5 in three patients (9.7%), 5.6-11 in 14 (45.2%), and 11.1-17.5 in eight (25.8%).</p><p><strong>Conclusions: </strong>Our findings confirm the ongoing use of DMTs in terminally ill patients and highlight their unmet need for palliative care. Including such patients into hospice programs may help avoid futile aggressive treatments, improve care appropriateness, and ensure better quality of life at the end of life.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"336-340"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148035559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of bio-psycho-social factors on mental health outcomes in patients with solid tumors.","authors":"Raffaela D G Sartori, Davide Dalu, Davide De Francesco, Valentina Biscaldi, Maria Silvia Cona, Anna Gambaro, Sabrina Ferrario, Lorenzo Ruggieri, Virginio Filipazzi, Cinzia Fasola, Cristina Marrazzo, Nicla La Verde","doi":"10.1177/03008916261442818","DOIUrl":"10.1177/03008916261442818","url":null,"abstract":"<p><strong>Introduction: </strong>The old oncology approach, which considered the clinical and performance status as the most relevant diseases course and well-being indexes, has been recently replaced by a care system also focusing on a person's characteristics and needs. This study analyzed the role of physical symptoms, illness awareness, individual activities and social contexts on anxious/depressive symptoms and mental health in localized (LP) and advanced/metastatic (AMP) cancer patients.</p><p><strong>Methods: </strong>Socio-demographic and medical information was gathered. The Revised Illness Perception Questionnaire, Hospital and Depression Anxiety Scale, and Mental Health Continuum Short-Form were administered.</p><p><strong>Results: </strong>One hundred and thirteen patients, 75 LP and 38 AMP, aged 27-82, were enrolled. Unique patterns of difficulties and resources emerged at different stages of cancer. AMP reported a worse quality of life in perceived illness persistence and treatments control, anxious/depressive symptoms, and psychological well-being. In LP, higher levels of anxious/depressive symptoms were associated with lack of hobbies, and higher perceived illness control was linked to higher mental health. LP did not report higher well-being than AMP. No significant differences in flourishing persons distributions were detected among groups. A multivariable model showed that the independent presence of pain and partner influenced higher levels of mental health more in AMP than in LP.</p><p><strong>Conclusion: </strong>Tailored intervention should enhance individuals' mental health and active resources mobilization.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"305-315"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to <i>KRAS</i> status: An Italian real-world study.","authors":"Alessandro Leonetti, Vanessa Callegari, Fabiana Perrone, Giuseppe Maglietta, Paola Bordi, Emilio Bria, Emanuele Vita, Francesco Gelsomino, Andrea De Giglio, Alain Gelibter, Marco Siringo, Francesca Mazzoni, Enrico Caliman, Carlo Genova, Giulia Barletta, Federica Bertolini, Giorgia Guaitoli, Francesco Passiglia, Marco Donatello Delcuratolo, Michele Montrone, Sara Oresti, Giulia Pasello, Elisa Roca, Lorenzo Belluomini, Fabiana Letizia Cecere, Annalisa Guida, Anna Manzo, Alessandro Russo, Francesca Rastelli, Alessandra Bulotta, Fabrizio Citarella, Luca Toschi, Federica Zoratto, Diego Luigi Cortinovis, Francesco Paoloni, Alessandro Follador, Annamaria Carta, Andrea Camerini, Flavio Salerno, Rosa Rita Silva, Editta Baldini, Corrado Ficorella, Matteo Brighenti, Matteo Santoni, Francesco Malorgio, Caterina Caminiti, Matteo Puntoni, Marcello Tiseo","doi":"10.1177/03008916261443123","DOIUrl":"10.1177/03008916261443123","url":null,"abstract":"<p><p>IntroductionChemo-immunotherapy is the standard frontline treatment of advanced non-squamous non-small cell lung cancer (nsq-NSCLC). Among oncogenic drivers, KRAS mutation accounts for approximately 25% of lung adenocarcinomas, with p.G12C being the most common variant. This study assessed clinical features and survival outcomes according to KRAS mutation in a real-life population of nsq-NSCLC patients treated with first-line platinum-pemetrexed-pembrolizumab.MethodsThis is a retrospective-prospective study including patients with nsq-NSCLC who received first-line platinum-pemetrexed-pembrolizumab from 4 September 2018 in 33 Italian Centers.ResultsAmong the 765 patients included in this analysis, 121 (15.8%) had <i>KRAS</i> p.G12C mutation, 201 (26.3%) <i>KRAS</i> non-p.G12C mutation and 443 (57.9%) <i>KRAS</i> WT. <i>KRAS</i>-mutated patients had more frequently a history of smoking (90.6% vs 84.1%, p=0.012) and bone metastases (44.1% vs 35.9%; p=0.022) compared to <i>KRAS</i> WT.Median Overall Survival (OS) was similar between <i>KRAS</i>-mutated and <i>KRAS</i> WT patients (16.7 vs 18.2 months; adjusted Hazard Ratio [HR] 1.19, 95% Confidence Interval [CI] 0.95-1.50, p=0.132). No difference in OS was found between <i>KRAS</i> p.G12C and <i>KRAS</i> non-p.G12C (15.9 vs 17.0 months, HR 0.93, 95% CI: 0.66-1.31, p=0.676).Median progression-free survival was significantly shorter in <i>KRAS</i>-mutated compared to <i>KRAS</i> WT patients (8.8 vs 10.8 months; adjusted HR 1.29, 95% CI 1.04-1.59, p=0.018), with no differences between <i>KRAS</i> p.G12C and <i>KRAS</i> non-p.G12C (8.8 vs 8.8 months, HR 0.95, 95% CI: 0.70-1.30, p=0.756).Conclusions<i>KRAS</i> mutation showed a potential negative predictive role in advanced nsq-NSCLC treated with first-line chemo-immunotherapy. The impact of co-mutations and post-progression outcomes warrants further investigation.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"316-324"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The \"empty speech bubbles\": Explaining cancer through play. A pediatric oncology unit pilot experience.","authors":"Olga Nigro, Annarita Adduci, Luca Bergamaschi, Giovanna Gattuso, Giovanna Sironi, Monica Giovanetti, Maura Massimino, Paolo Grampa","doi":"10.1177/03008916261438276","DOIUrl":"10.1177/03008916261438276","url":null,"abstract":"<p><strong>Purpose: </strong>This pilot study aimed at evaluating the feasibility and acceptability of a structured psycho-educational intervention designed to increase disease awareness in children with tumors. The primary objective was to promote psychological adjustment by supporting children's understanding of their illness and facilitating open parent-child communication about cancer.</p><p><strong>Methods: </strong>Consecutive patients aged 6-11 years undergoing diagnosis or treatment for tumors at a single pediatric oncology center were invited to participate in a four-month period. The intervention consisted of three stages: (1) development of a mini guidebook for caregivers; (2) a psychologist-led meeting with parents focused on communication strategies; and (3) individual or group educational activities with children conducted by a multidisciplinary team. Child-centered, age-appropriate methods-including play, creative tasks, and anonymous \"empty speech bubbles\" for questions-were used to address disease etiology, diagnostic procedures, treatments, and terminology.</p><p><strong>Results: </strong>Eleven children participated in the intervention. All engaged actively in the sessions and expressed reassurance and satisfaction with the information received. The use of anonymous question tools facilitated open expression of fears and doubts. Parents reported increased confidence and reduced difficulty in communicating with their child about the illness, valuing the structured guidance provided.</p><p><strong>Conclusion: </strong>This preliminary experience suggests that structured, interactive interventions promoting illness awareness are feasible and well accepted in pediatric oncology. Such approaches may support psychological adjustment in children with tumors and improve parent-child communication, representing a valuable component of holistic cancer care.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"288-296"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147782228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ten tips to reduce gaps in daily oncology practice.","authors":"Luca Moscetti, Antonella Ferro, Catia Angiolini, Ornella Garrone, Palma Fedele, Sara Donati, Lorenzo Gianni","doi":"10.1177/03008916261437958","DOIUrl":"10.1177/03008916261437958","url":null,"abstract":"<p><p>The daily practice of oncology in Italy is increasingly strained, with bureaucratic rigidity making routine clinical work progressively more difficult. A panel of clinical oncologists, reunited in the DonnaRosa Group, an emerging model of community-based collaboration, where clinicians share real-world challenges and develop actionable strategies, debate the points with the aim of producing some tips to close the gap in clinical practice.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"282-287"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147634625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Self-perceived attitudes of Italian oncology nurses towards clinical trial involvement: A cohort observational study\".","authors":"","doi":"10.1177/03008916251335901","DOIUrl":"10.1177/03008916251335901","url":null,"abstract":"","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"366"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13579113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimising combination therapy for paediatric, adolescent and young adult patients with non-rhabdomyosarcoma soft tissue sarcomas: The OCTOPUS platform trial.","authors":"Reineke A Schoot, Michela Casanova, Kelly van Bindsbergen, Bernadette Brennan, Willemijn Breunis, Daniela Di Carlo, Nadege Corradini, Raquel Davila Fajardo, Walter Ferrari Bravo, Gabriela Guillén Burrieza, Martha Grootenhuis, Shushan Hovsepyan, Alwin D R Huitema, Michael T Meister, Lucy Metayer, Max M van Noesel, Daniel Orbach, David Riedl, Sheila Terwisscha van Scheltinga, Harm van Tinteren, Daria Valerio, Nicole Scobie, Andrea Ferrari","doi":"10.1177/03008916261456574","DOIUrl":"https://doi.org/10.1177/03008916261456574","url":null,"abstract":"<p><p>Few innovative treatments were developed for patients with non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) in the past decades. The paper describes the OCTOPUS project (Optimising Combination Therapy fOr Paediatric, adolescent and yoUng adult patients with non-rhabdomyosarcoma soft tissue Sarcomas), a master protocol and includes an adaptive platform trial comprising different sub-trials, a real-world data registry, translational studies, and overarching study questions assessing local therapy issues and patient reported outcome measures (PROMs). The OCTOPUS consortium will provide an operational framework including a legal consortium structure, a network of national coordinating centres (NCCs) and sites within the EpSSG (European paediatric Soft tissue sarcoma Study Group) and ITCC (Innovative Therapies for Children and adolescents with Cancer) network. The overarching aim of the platform is to improve outcome and quality of life for patients with NRSTS by providing access to innovative treatments. Every sub-trial will have a unique design, tailored to the needs of the patients, the characteristics of the disease, and the stage of development of the experimental compound(s). Depending on the medical need in a specific patient population and the expected activity of a compound (or a combination), the innovative treatment(s) will be offered to patients with relapsed/refractory disease or placed in frontline treatment when appropriate.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261456574"},"PeriodicalIF":2.0,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148631599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancer.","authors":"Chiara Benvenuti, Alessandro Viansone, Flavia Jacobs, Thomas Grinda, Jean Zeghondy, Mariangela Gaudio, Laura Clapis, Riccardo Gerosa, Jacopo Canzian, Caroline Poisson, Meriem Mokdad-Adi, Paola Tiberio, Giuseppe Saltalamacchia, Alberto Zambelli, Armando Santoro, Barbara Pistilli, Rita De Sanctis","doi":"10.1177/03008916261454865","DOIUrl":"https://doi.org/10.1177/03008916261454865","url":null,"abstract":"<p><p>Background and aimThere is limited data on the safety of switching between CDK4/6i to address toxicity-related permanent discontinuation in patients with HR+/HER2- advanced breast cancer (ABC).To overcome this issue, this international observational study included consecutive HR+/HER2- ABC patients treated with CDK4/6i at two cancer centers, who switched the CDK4/6i for toxicity. The study aimed to evaluate the safety, feasibility, and clinical impact of this approach.ResultsAmong 1413 patients, 67 (4.5%) switched CDK4/6i due to toxicity. The median time to switch was three months. Adverse events leading to switch were mainly hematologic and hepatic. Recurrence of the same toxicity occurred in 30% of patients, but with lower severity for neutropenia (p=0.047) and hepatotoxicity (p=0.005). Notably, among the 67 patients who switched CDK4/6i, only seven (10%) ultimately required permanent discontinuation of the second CDK4/6i for toxicity, primarily for abemaciclib-induced diarrhea, suggesting that switching may represent a promising strategy to avoid treatment interruption. Median progression-free survival from the start of the first CDK4/6i was 16.8 monthsConclusionIn conclusion, switching CDK4/6i appears to be a safe and pragmatic strategy to address toxicity-related permanent discontinuation of CDK4/6i.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261454865"},"PeriodicalIF":2.0,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148631594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preliminary study on intravesical instillation of IL-12 mRNA lipid nanoparticles for the treatment of bladder cancer.","authors":"Bangjie Ouyang, Zhaofeng Wu, Jiawen Li, Guanqiang Zhu, Yuanyuan Shen, Meidong Lang","doi":"10.1177/03008916261463130","DOIUrl":"10.1177/03008916261463130","url":null,"abstract":"<p><strong>Purpose: </strong>The present study aims to investigate the feasibility and therapeutic potential of intravesically administered interleukin-12 mRNA-loaded lipid nanoparticles (IL-12 mRNA LNPs) for treatment of orthotopic bladder cancer.</p><p><strong>Methods: </strong>Fluc-mRNA LNPs and IL-12 mRNA LNPs were prepared using microfluidic technology and characterized in terms of particle size, zeta potential, encapsulation efficiency, and stability. The <i>in vivo</i> transfection efficiency of the Fluc-mRNA LNPs were assessed by bioluminescence imaging. The antitumor efficacy of IL-12 mRNA LNPs was valuated in orthotopic bladder cancer mice models which were established with Luc-MB49 cells.</p><p><strong>Results: </strong>Fluc-mRNA LNPs and IL-12 mRNA LNPs were successfully prepared via microfluidics, which had uniform particle size (101.6 nm and 104.4 nm), near-neutral surface charge (-3.39 mV and -8.34 mV), high encapsulation efficiency (89.01% and 98.87%), and good stability. Efficient intravesical transfection and robust protein expression were confirmed in mouse bladders using an <i>in vivo</i> bioluminescence imaging. In orthotopic bladder cancer-bearing mice, intravesical instillation of IL-12 mRNA LNPs significantly inhibited tumor growth.</p><p><strong>Conclusions: </strong>Intravesical delivery of IL-12 mRNA LNPs represents an effective and promising strategy for local immunotherapy of bladder cancer. These findings provide experimental evidence supporting the potential clinical translation of mRNA-LNPs-based intravesical regimens for the treatment of bladder cancer.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261463130"},"PeriodicalIF":2.0,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148580212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Caring for the mental health of cancer patients: Systematic review of mental adaptation to cancer.","authors":"Diana Elena Lazar Balan, Roxana Postolica, Teodora Alexa-Stratulat, Asmaa Waheed Mohamed, Bianca Hanganu, Beatrice Gabriela Ioan","doi":"10.1177/03008916261452564","DOIUrl":"https://doi.org/10.1177/03008916261452564","url":null,"abstract":"<p><strong>Aim: </strong>This review aims to describe the literature on mental adaptation to cancer and to examine how coping strategies influence psychological outcomes among cancer patients.</p><p><strong>Research questions: </strong>What coping strategies related to mental adaptation to cancer are reported among patients with breast, lung, colorectal, prostate, and bladder cancers?</p><p><strong>Design: </strong>Systematic review reported according to the PRISMA guidelines.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted in the PubMed database. Study methodological quality was evaluated using the Joanna Briggs Institute critical appraisal tools, and the certainty of evidence was assessed according to the Oxford Centre for Evidence-Based Medicine. Article selection, quality assessment, and risk-of-bias evaluation were conducted independently by two reviewers.</p><p><strong>Results: </strong>The search identified 173,274 records, of which 42 studies met the eligibility criteria after screening. Most studies were cross-sectional and conducted in hospital oncology departments, outpatient clinics, rehabilitation programs, or community follow-up services. Findings indicate that the diagnostic and early treatment phases represent the most psychologically vulnerable periods for cancer patients. Maladaptive coping strategies, particularly helplessness-hopelessness and anxious preoccupation, were associated with increased psychological distress, including anxiety and depression. Sociodemographic factors such as age, gender, education, income, and social support also influenced psychological outcomes.</p><p><strong>Conclusion: </strong>Early psychological assessment and psychosocial interventions during the first months after diagnosis may improve mental health outcomes. Further research should explore digital health tools and remote support systems to enhance psychological care for cancer patients.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261452564"},"PeriodicalIF":2.0,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148536934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}